MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- AUROBINDO PHARMA - ABBOTT INDIA
AUROBINDO PHARMA vs ABBOTT INDIA - Comparison Results
AUROBINDO PHARMA Change
Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More
ABBOTT INDIA 
Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More
Current Valuations
| AUROBINDO PHARMA | ABBOTT INDIA | AUROBINDO PHARMA/ ABBOTT INDIA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 14.2 | 43.6 | 32.6% | View Chart |
| P/BV | x | 3.1 | 12.5 | 24.8% | View Chart |
| Dividend Yield | % | 0.4 | 0.6 | 73.3% |
Financials
 AUROBINDO PHARMA  ABBOTT INDIA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| AUROBINDO PHARMA Mar-18 |
ABBOTT INDIA Mar-18 |
AUROBINDO PHARMA/ ABBOTT INDIA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 809 | 6,110 | 13.2% | |
| Low | Rs | 504 | 3,996 | 12.6% | |
| Sales per share (Unadj.) | Rs | 281.1 | 1,552.2 | 18.1% | |
| Earnings per share (Unadj.) | Rs | 41.4 | 188.8 | 21.9% | |
| Cash flow per share (Unadj.) | Rs | 50.9 | 196.4 | 25.9% | |
| Dividends per share (Unadj.) | Rs | 2.50 | 55.00 | 4.5% | |
| Dividend yield (eoy) | % | 0.4 | 1.1 | 35.0% | |
| Book value per share (Unadj.) | Rs | 199.4 | 796.6 | 25.0% | |
| Shares outstanding (eoy) | m | 585.88 | 21.25 | 2,757.1% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 2.3 | 3.3 | 71.8% | |
| Avg P/E ratio | x | 15.9 | 26.8 | 59.3% | |
| P/CF ratio (eoy) | x | 12.9 | 25.7 | 50.2% | |
| Price / Book Value ratio | x | 3.3 | 6.3 | 51.9% | |
| Dividend payout | % | 6.0 | 29.1 | 20.8% | |
| Avg Mkt Cap | Rs m | 384,630 | 107,376 | 358.2% | |
| No. of employees | `000 | 17.3 | 3.3 | 521.7% | |
| Total wages/salary | Rs m | 21,308 | 3,937 | 541.2% | |
| Avg. sales/employee | Rs Th | 9,500.7 | 9,929.3 | 95.7% | |
| Avg. wages/employee | Rs Th | 1,229.4 | 1,185.1 | 103.7% | |
| Avg. net profit/employee | Rs Th | 1,397.9 | 1,207.7 | 115.7% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 164,666 | 32,985 | 499.2% | |
| Other income | Rs m | 1,020 | 1,170 | 87.2% | |
| Total revenues | Rs m | 165,686 | 34,155 | 485.1% | |
| Gross profit | Rs m | 37,718 | 5,245 | 719.1% | |
| Depreciation | Rs m | 5,580 | 162 | 3,446.4% | |
| Interest | Rs m | 777 | 38 | 2,034.6% | |
| Profit before tax | Rs m | 32,380 | 6,215 | 521.0% | |
| Minority Interest | Rs m | 31 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 8,183 | 2,203 | 371.5% | |
| Profit after tax | Rs m | 24,229 | 4,012 | 603.9% | |
| Gross profit margin | % | 22.9 | 15.9 | 144.0% | |
| Effective tax rate | % | 25.3 | 35.4 | 71.3% | |
| Net profit margin | % | 14.7 | 12.2 | 121.0% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 121,878 | 22,655 | 538.0% | |
| Current liabilities | Rs m | 86,806 | 6,681 | 1,299.3% | |
| Net working cap to sales | % | 21.3 | 48.4 | 44.0% | |
| Current ratio | x | 1.4 | 3.4 | 41.4% | |
| Inventory Days | Days | 130 | 65 | 200.5% | |
| Debtors Days | Days | 68 | 29 | 234.5% | |
| Net fixed assets | Rs m | 81,037 | 835 | 9,699.6% | |
| Share capital | Rs m | 586 | 213 | 275.7% | |
| "Free" reserves | Rs m | 116,218 | 16,715 | 695.3% | |
| Net worth | Rs m | 116,804 | 16,928 | 690.0% | |
| Long term debt | Rs m | 4,512 | 0 | - | |
| Total assets | Rs m | 211,052 | 24,162 | 873.5% | |
| Interest coverage | x | 42.7 | 163.7 | 26.1% | |
| Debt to equity ratio | x | 0 | 0 | - | |
| Sales to assets ratio | x | 0.8 | 1.4 | 57.2% | |
| Return on assets | % | 11.8 | 16.8 | 70.7% | |
| Return on equity | % | 20.7 | 23.7 | 87.5% | |
| Return on capital | % | 27.4 | 36.9 | 74.1% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 80,727 | 369 | 21,904.6% | |
| Fx outflow | Rs m | 34,700 | 3,807 | 911.6% | |
| Net fx | Rs m | 46,027 | -3,438 | -1,338.8% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 19,548 | 1,527 | 1,280.2% | |
| From Investments | Rs m | -19,570 | -2,148 | 910.9% | |
| From Financial Activity | Rs m | 8,642 | -1,024 | -843.6% | |
| Net Cashflow | Rs m | 8,922 | -1,646 | -542.2% | |
Share Holding
| Indian Promoters | % | 54.1 | 0.0 | - | |
| Foreign collaborators | % | 0.0 | 75.0 | - | |
| Indian inst/Mut Fund | % | 8.0 | 7.9 | 100.6% | |
| FIIs | % | 27.7 | 0.1 | 27,700.0% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 10.2 | 17.1 | 59.6% | |
| Shareholders | 69,601 | 18,270 | 381.0% | ||
| Pledged promoter(s) holding | % | 8.6 | 0.0 | - |
Compare AUROBINDO PHARMA With: STRIDES PHARMA SCIENCE AJANTA PHARMA UNICHEM LAB ALEMBIC PHARMA ELDER PHARMA
Compare AUROBINDO PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Trades Marginally Higher; Tata Steel & Bajaj Finance Top Gainers(12:30 pm)
Share markets in India are presently trading on a positive note, tracking gains in global peers. US President Donald Trump said he did not want war.
Related Views on News
ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)
Aug 8, 2019 | Updated on Aug 8, 2019For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)
Aug 8, 2019 | Updated on Aug 8, 2019For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)
May 30, 2019 | Updated on May 30, 2019For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)
May 28, 2019 | Updated on May 28, 2019For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
ABBOTT INDIA Announces Quarterly Results (3QFY19); Net Profit Up 1.4% (Quarterly Result Update)
Feb 12, 2019 | Updated on Feb 12, 2019For the quarter ended December 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 1.4% YoY). Sales on the other hand came in at Rs 9 bn (up 7.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
More Views on NewsMost Popular
Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)
Sep 5, 2019Everyone dreams of owning a business. Here is your chance.
7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)
Sep 5, 2019The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?
Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)
Sep 12, 2019News headlines predict gloom and doom for India these days. You should ignore them.
A Recession Proof Stock You Can Bet On(Profit Hunter)
Sep 10, 2019Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.
This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)
Sep 11, 2019How financial inclusion provides a big runway for this stock recommendation.
MoreAUROBINDO PHARMA SHARE PRICE
Sep 18, 2019 12:27 PM
TRACK AUROBINDO PHARMA
- Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON AUROBINDO PHARMA
AUROBINDO PHARMA 5-YR ANALYSIS
COMPARE AUROBINDO PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.